MDM2 and myelodysplastic syndrome: Currently, eight phase I/II clinical trials are ongoing for AML and MDS with MBG453 monotherapy or the combination of different agents such as hypomethylating agents (HMAs), PD-1 inhibitors, HDM201 (an MDM2 inhibitor), and venetoclax.